Herceptin® Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials

Publisher： Karger

E-ISSN： 1423-0232|61|2|14-21

ISSN： 0030-2414

Source： Oncology, Vol.61, Iss.2, 2001-10, pp. : 14-21

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2++ metastatic breast cancer with letrozole alone or in combination with lapatinib

By Sherrill Beth   Sherif Bintu   Amonkar Mayur M.   Maltzman Julie   O’Rourke Lisa   Johnston Stephen  

Current Medical Research and Opinion, Vol. 27, Iss. 12, 2011-12 ,pp. : 2245-2252

Informa Healthcare

Access to resources Recommend Favorite

Adjuvant Chemotherapy for the Treatment of HER2-Positive Early Breast Cancer

By  

Oncology, Vol. 77, Iss. 1, 2010-02 ,pp. : 14-17

Karger

Access to resources Recommend Favorite

What Can We Learn from Herceptin® Trials in Metastatic Breast Cancer?

By  

Oncology, Vol. 63, Iss. 1, 2002-11 ,pp. : 39-46

Karger

Access to resources Recommend Favorite

Docetaxel plus trastuzumab as treatment for HER-2 positive metastatic breast cancer: review of the existing evidence

By Demonty Gaston  

Women's Health, Vol. 3, Iss. 5, 2007-09 ,pp. : 523-528

Future Medicine

Access to resources Recommend Favorite

Combination of Trastuzumab and Triple FLOT Chemotherapy (5-Fluorouracil/Leucovorin, Oxaliplatin, and Docetaxel) in Patients with HER2-Positive Metastatic Gastric Cancer: Report of 3 Cases

By  

Oncology Research and Treatment, Vol. 35, Iss. 9, 2012-08 ,pp. : 505-508

Karger

Access to resources Recommend Favorite